@article{SeegersZabelGrueteretal.2015,
  author    = {Seegers, Joachim and Zabel, Markus and Gr{\"u}ter, Timo and Ammermann, Antje and Weber-Kr{\"u}ger, Mark and Edelmann, Frank and Gelbrich, G{\"o}tz and Binder, Lutz and Herrmann-Lingen, Christoph and Gr{\"o}schel, Klaus and Hasenfuß, Gerd and Feltgen, Nicolas and Pieske, Burkert and Wachter, Rolf},
  title     = {Natriuretic peptides for the detection of paroxysmal atrial fibrillation},
  series = {Open Heart},
  volume    = {2},
  journal   = {Open Heart},
  number    = {e000182},
  doi       = {10.1136/openhrt-2014-000182},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-149939},
  year      = {2015},
  abstract  = {Background and purpose: Silent atrial fibrillation (AF) and tachycardia (AT) are considered precursors of ischaemic stroke. Therefore, detection of paroxysmal atrial rhythm disorders is highly relevant, but is clinically challenging. We aimed to evaluate the diagnostic value of natriuretic peptide levels in the detection of paroxysmal AT/AF in a pilot study. Methods: Natriuretic peptide levels were analysed in two independent patient cohorts (162 patients with arterial hypertension or other cardiovascular risk factors and 82 patients with retinal vessel disease). N-terminal-pro-brain natriuretic peptide (NT-proBNP) and BNP were measured before the start of a 7-day Holter monitoring period carefully screened for AT/AF. Results: 244 patients were included; 16 had paroxysmal AT/AF. After excluding patients with a history of AT/AF (n=5), 14 patients had newly diagnosed AT/AF (5.8\%) NT-proBNP and BNP levels were higher in patients with paroxysmal AT/AF in both cohorts: (1) 154.4 (IQR 41.7; 303.6) versus 52.8 (30.4; 178.0) pg/mL and 70.0 (31.9; 142.4) versus 43.9 (16.3; 95.2) and (2) 216.9 (201.4; 277.1) versus 90.8 (42.3-141.7) and 96.0 (54.7; 108.2) versus 29.1 (12.0; 58.1). For the detection of AT/AF episodes, NT-proBNP and BNP had an area under the curve in receiver operating characteristic analysis of 0.76 (95\% CI, 0.64 to 0.88; p=0.002) and 0.75 (0.61 to 0.89; p=0.004), respectively. Conclusions: NT-proBNP and BNP levels are elevated in patients with silent AT/AF as compared with sinus rhythm. Thus, screening for undiagnosed paroxysmal AF using natriuretic peptide level initiated Holter monitoring may be a useful strategy in prevention of stroke or systemic embolism.},
  language  = {en}
}
@article{JochmannElkenaniMohamedetal.2019,
  author    = {Jochmann, Svenja and Elkenani, Manar and Mohamed, Belal A. and Buchholz, Eric and Lbik, Dawid and Binder, Lutz and Lorenz, Kristina and Shah, Ajay M. and Hasenfuß, Gerd and Toischer, Karl and Schnelle, Moritz},
  title     = {Assessing the role of extracellular signal-regulated kinases 1 and 2 in volume overload-induced cardiac remodelling},
  series = {ESC Heart Failure},
  volume    = {6},
  journal   = {ESC Heart Failure},
  number    = {5},
  doi       = {10.1002/ehf2.12497},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-212735},
  pages     = {1015 -- 1026},
  year      = {2019},
  abstract  = {Aims Volume overload (VO) and pressure overload (PO) induce differential cardiac remodelling responses including distinct signalling pathways. Extracellular signal-regulated kinases 1 and 2 (ERK1/2), key signalling components in the mitogen-activated protein kinase (MAPK) pathways, modulate cardiac remodelling during pressure overload (PO). This study aimed to assess their role in VO-induced cardiac remodelling as this was unknown. Methods and results Aortocaval fistula (Shunt) surgery was performed in mice to induce cardiac VO. Two weeks of Shunt caused a significant reduction of cardiac ERK1/2 activation in wild type (WT) mice as indicated by decreased phosphorylation of the TEY (Thr-Glu-Tyr) motif (-28\% as compared with Sham controls, P < 0.05). Phosphorylation of other MAPKs was unaffected. For further assessment, transgenic mice with cardiomyocyte-specific ERK2 overexpression (ERK2tg) were studied. At baseline, cardiac ERK1/2 phosphorylation in ERK2tg mice remained unchanged compared with WT littermates, and no overt cardiac phenotype was observed; however, cardiac expression of the atrial natriuretic peptide was increased on messenger RNA (3.6-fold, P < 0.05) and protein level (3.1-fold, P < 0.05). Following Shunt, left ventricular dilation and hypertrophy were similar in ERK2tg mice and WT littermates. Left ventricular function was maintained, and changes in gene expression indicated reactivation of the foetal gene program in both genotypes. No differences in cardiac fibrosis and kinase activation was found amongst all experimental groups, whereas apoptosis was similarly increased through Shunt in ERK2tg and WT mice. Conclusions VO-induced eccentric hypertrophy is associated with reduced cardiac ERK1/2 activation in vivo. Cardiomyocyte-specific overexpression of ERK2, however, does not alter cardiac remodelling during VO. Future studies need to define the pathophysiological relevance of decreased ERK1/2 signalling during VO.},
  language  = {en}
}
@article{EdelmannStahrenbergGelbrichetal.2011,
  author    = {Edelmann, Frank and Stahrenberg, Raoul and Gelbrich, G{\"o}tz and Durstewitz, Kathleen and Angermann, Christiane E. and D{\"u}ngen, Hans-Dirk and Scheffold, Thomas and Zugck, Christian and Maisch, Bernhard and Regitz-Zagrosek, Vera and Hasenfuß, Gerd and Pieske, Burkert M. and Wachter, Rolf},
  title     = {Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction},
  series = {Clinical Research in Cardiology},
  volume    = {100},
  journal   = {Clinical Research in Cardiology},
  number    = {9},
  doi       = {10.1007/s00392-011-0305-4},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-134354},
  pages     = {755-764},
  year      = {2011},
  abstract  = {Background Comorbidities negatively affect prognosis more strongly in heart failure with preserved (HFpEF) than with reduced (HFrEF) ejection fraction. Their comparative impact on physical impairment in HFpEF and HFrEF has not been evaluated so far. Methods and results The frequency of 12 comorbidities and their impact on NYHA class and SF-36 physical functioning score (SF-36 PF) were evaluated in 1,294 patients with HFpEF and 2,785 with HFrEF. HFpEF patients had lower NYHA class (2.0 ± 0.6 vs. 2.4 ± 0.6, p < 0.001) and higher SF-36 PF score (54.4 ± 28.3 vs. 54.4 ± 27.7, p < 0.001). All comorbidities were significantly (p < 0.05) more frequent in HFrEF, except hypertension and obesity, which were more frequent in HFpEF (p < 0.001). Adjusting for age and gender, COPD, anemia, hyperuricemia, atrial fibrillation, renal dysfunction, cerebrovascular disease and diabetes had a similar (p for interaction > 0.05) negative effect in both groups. Obesity, coronary artery disease and peripheral arterial occlusive disease exerted a significantly (p < 0.05) more adverse effect in HFpEF, while hypertension and hyperlipidemia were associated with fewer (p < 0.05) symptoms in HFrEF only. The total impact of comorbidities on NYHA (AUC for prediction of NYHA III/IV vs. I/II) and SF-36 PF (r 2) in multivariate analyses was approximately 1.5-fold higher in HFpEF, and also much stronger than the impact of a 10\% decrease in ejection fraction in HFrEF or a 5 mm decrease in left ventricular end-diastolic diameter in HFpEF. Conclusion The impact of comorbidities on physical impairment is higher in HFpEF than in HFrEF. This should be considered in the differential diagnosis and in the treatment of patients with HFpEF.},
  language  = {en}
}